New research suggests that individuals who stop using new GLP-1 drugs like Wegovy and Mounjaro tend to recover lost weight at a significantly accelerated pace than those who halt traditional lifestyle programs.
Published data in a prominent health publication demonstrates that while obese individuals can lose substantial amounts of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Users buying such treatments should be aware of the danger of fast weight regain when the therapy concludes," stated expert Dr. Susan Jebb.
That rate of regain suggests a return to original weight within about 18 months.
Analyzing Approaches
The analysis, which reviewed dozens of trials involving thousands of participants, compared the effects of GLP-1 agonists with conventional dieting.
Researchers point out that individuals who shed pounds through dieting typically see a more gradual creep back—perhaps 100 grams monthly—after stopping.
Explaining the Rapid Regain
Doctors propose the way of the drugs explains the accelerated regain.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production might result in the system to produce less of its endogenous GLP-1, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' means hunger is no longer kept in check, making excessive eating much more probable."
A Lifelong Condition?
Medical guidelines recommend the jabs for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Many experts contend that, due to the significant potential of relapse, the therapy might need to be ongoing.
This perspective is echoed by pharmaceutical companies, who say that the results "highlight the chronic character of obesity," akin to managing diseases like high blood pressure.
Patient Experiences
Individuals who have come off the medication report a sudden resurgence of hunger.
"I experienced a switch flipping and I was suddenly extremely hungry," said an individual.
This challenge is compounded if patients have not adopted permanent lifestyle or habit modifications during treatment.
Growing Use
Survey data indicate that millions of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Use is higher among women compared to males.
- The middle-aged demographic shows the highest usage rates.
- Many access the medications through private prescriptions rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are potent tools for weight loss, they are not a magic fix and maintained weight loss hinges on combined behavioural changes.
